# Longitudinal multiphoton imaging of cerebral amyloid angiopathy in response to anti-ApoE4 immunotherapy in mice.

- **DOI:** [10.1186/s13024-026-00957-x](https://doi.org/10.1186/s13024-026-00957-x)
- **Rating:** Sound (3.7 out of 5)
- **Verdict:** Longitudinal imaging narrows HAE-4’s therapeutic mechanism, but cranial-window constraints and unsupported comparative-safety framing limit its translational force.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1186%2Fs13024-026-00957-x

## Key claims

1. there was a modest shrinkage of the smallest parenchymal fibrillar plaques but that fibrillar CAA on pial arterioles was not actively removed
   - Support: Tentative
   - Type: Primary finding
   - Basis: CAA was tracked longitudinally, but plaque shrinkage followed post hoc size stratification after a null total-area result
   - Location: Results, first subsection
2. there was no treatment-associated improvement in vascular function in cortical arterioles in the areas measured in vivo
   - Support: Supported
   - Type: Secondary
   - Basis: multiple longitudinal vessel measures were unchanged, although samples were modest and no baseline deficit was present
   - Location: Abstract; Results, Figs. 2–4
3. In 5xFAD mice treated without a cranial window, there was a reduction in plaques and CAA as previously described in HAE-4 vs. control treated mice
   - Support: Supported
   - Type: Secondary
   - Basis: the larger nonsurgical cohort showed consistent terminal reductions, though detailed methods were deferred to supplementary material
   - Location: Abstract; Results, Fig. 6

## Strengths

- **Longitudinal tracking answers the mechanism question** Repeated multiphoton imaging followed the same CAA-bearing vessels and plaques before and during treatment, directly testing whether existing deposits were removed rather than inferring clearance from terminal burden.
  - Dimension: contribution
  - Location: Methods, Treatment Paradigm and Vascular and CAA Imaging; Fig. 1
- **Blinded animal-level experimental execution** The experimenter was blinded during dose preparation, injections, data collection, and analysis; fields were selected before treatment; and figure legends identify the animal average as the statistical unit.
  - Dimension: methodological rigour
  - Location: Methods, Treatment Paradigm; Figs. 1–6
- **Discordant findings receive integrated analysis** The Discussion distinguishes superficial longitudinal imaging from hemisphere-level histology and examines assay, surgery, timing, pathology stage, and sampling as explanations for disagreement with prior work.
  - Dimension: positioning
  - Location: Discussion, sections addressing prior vascular-function findings and post-mortem discordance

## Limitations

- **Small-plaque result is post hoc** Total parenchymal plaque area was not significantly changed before plaques were divided into four size groups, after which only the smallest group showed a treatment effect. No multiplicity correction across these exploratory comparisons is described.
  - Dimension: methodological rigour
  - Location: Results, first subsection; Fig. 1D–F
- **Window and cohort differences confound interpretation** CAA was not reduced in the small terminal windowed cohort but was reduced in a larger, younger nonsurgical cohort treated for a different duration. These differences prevent a clean attribution of the discordance to the cranial window.
  - Dimension: contribution
  - Location: Results, Figs. 5D and 6D/G; Discussion
- **Comparative safety claim exceeds design** The absence of a treatment-associated hemorrhage signal in mice does not establish HAE-4 as safer than anti-Aβ immunotherapy because the current study lacks a concurrent anti-Aβ comparator and reports immune activation.
  - Dimension: reporting
  - Location: Abstract; Results, Figs. 5–6; Conclusions

## Reliability checks

No concerns (4 of 4 checks).

- **Results check:** Clean. The reported numbers and statistics are consistent with the stated results.
- **Reporting and transparency:** Clean. No grounded reporting or conduct finding remains; antibody manufacture alone does not establish an undisclosed conflict of interest.
  - Conflict of interest: not stated · Ethics approval: declared · Data availability: not stated · Code availability: not stated
- **Reference integrity:** Clean
  - 33 references in manuscript
  - 32 of 32 checkable references found in an index
  - 1 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
